JP2012102100A5 - - Google Patents

Download PDF

Info

Publication number
JP2012102100A5
JP2012102100A5 JP2011247036A JP2011247036A JP2012102100A5 JP 2012102100 A5 JP2012102100 A5 JP 2012102100A5 JP 2011247036 A JP2011247036 A JP 2011247036A JP 2011247036 A JP2011247036 A JP 2011247036A JP 2012102100 A5 JP2012102100 A5 JP 2012102100A5
Authority
JP
Japan
Prior art keywords
antagonist
hepatitis
antibody
treatment
specifically recognizes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011247036A
Other languages
English (en)
Japanese (ja)
Other versions
JP5938876B2 (ja
JP2012102100A (ja
Filing date
Publication date
Priority claimed from US12/945,153 external-priority patent/US8440195B2/en
Application filed filed Critical
Publication of JP2012102100A publication Critical patent/JP2012102100A/ja
Publication of JP2012102100A5 publication Critical patent/JP2012102100A5/ja
Application granted granted Critical
Publication of JP5938876B2 publication Critical patent/JP5938876B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011247036A 2010-11-12 2011-11-11 Ｃｄ６９アンタゴニストを含む肝炎治療用組成物 Active JP5938876B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/945,153 US8440195B2 (en) 2010-11-12 2010-11-12 Inhibition of CD69 for treatment of inflammatory conditions
US12/945,153 2010-11-12

Publications (3)

Publication Number Publication Date
JP2012102100A JP2012102100A (ja) 2012-05-31
JP2012102100A5 true JP2012102100A5 (enExample) 2015-01-22
JP5938876B2 JP5938876B2 (ja) 2016-06-22

Family

ID=46047944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011247036A Active JP5938876B2 (ja) 2010-11-12 2011-11-11 Ｃｄ６９アンタゴニストを含む肝炎治療用組成物

Country Status (2)

Country Link
US (2) US8440195B2 (enExample)
JP (1) JP5938876B2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440195B2 (en) 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
WO2018074610A1 (ja) * 2016-10-21 2018-04-26 国立大学法人山口大学 Ｃｄ６９アンタゴニストを含む劇症型急性肺炎治療用組成物
JP6944701B2 (ja) * 2016-10-21 2021-10-06 国立大学法人山口大学 ＣＤ１１ｂアンタゴニストを含む劇症型急性肺炎治療用組成物
EP4622631A1 (en) 2022-11-23 2025-10-01 University of Georgia Research Foundation, Inc. Compositions and methods of use thereof for increasing immune responses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794132B2 (en) * 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
CN1322897C (zh) * 2000-02-21 2007-06-27 应用研究系统Ars股份公司 Il－18抑制剂的应用
EP2347767A3 (en) * 2003-01-31 2013-06-12 Albor Biologics, Inc. Immune regulation based on the targeting of early activation molecules
US20070274993A1 (en) * 2003-05-23 2007-11-29 Immuno-Biological Laboratories Co., Ltd. Immunocompetent Cell Activation Inhibitor and Use Thereof
KR20060052681A (ko) * 2003-05-23 2006-05-19 와이어쓰 Ｇｉｔｒ 리간드, ｇｉｔｒ 리간드-연관 분자, 항체 및그의 용도
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
JP2007022993A (ja) * 2005-07-20 2007-02-01 Chiba Univ アレルギー性喘息の治療薬
US8440195B2 (en) 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions

Similar Documents

Publication Publication Date Title
JP2013546230A5 (enExample)
IL254422A0 (en) Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
JP2012171428A5 (enExample)
JP2012046524A5 (enExample)
WO2010036395A3 (en) Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
JP2013540852A5 (enExample)
JP2008056926A5 (enExample)
AR089711A1 (es) Inhibidores del virus de hepatitis c
EP2493497A4 (en) NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME
JP2015504870A5 (enExample)
JP2013522425A5 (enExample)
HK1199640A1 (en) Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP2013522008A5 (enExample)
EP2521453A4 (en) METHOD AND COMPOSITIONS FOR TREATING MIGRAINE
JP2015526577A5 (enExample)
BRPI1000031A2 (pt) métodos para tratar de modo durável a esclerose múltipla em um paciente, para tratar eficazmente a esclerose múltipla em um paciente em um período de tempo crônico, para aumentar a capacidade de caminhar e para tratar os sintomas de esclerose múltipla, e, composição
CL2008000666A1 (es) Compuestos derivados de triciclos sustituidos, inhibidores del transportador de metales divalentes-1; y uso para tratar una enfermedad asociada con un trastorno del hierro.
JP2012102100A5 (enExample)
TN2011000204A1 (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
IL211810A0 (en) Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis
JP2011510778A5 (enExample)
JP2014526564A5 (enExample)
EA201401286A1 (ru) Композиции и способы для лечения синдрома раздраженной толстой кишки с помощью 5-аминосалицилата
BR112014002335A2 (pt) mictório e processo para troca de sifão de mictório